Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768246 | 0.93 | PTGDR2 (0.72) | PTGDR2 | |
| SCHEMBL5015664 | 0.92 | PTGDR2 (0.71) | PTGDR2 | |
| Qav680 SCHEMBL1941180 | 0.86 | PTGDR2 (1.00) | PTGDR2 | |
| Qav680 SCHEMBL29376454 | 0.86 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1940509 | 0.85 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1939422 | 0.83 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1940100 | 0.83 | PTGDR2 (0.88) | PTGDR2 | |
| SCHEMBL1940719 | 0.82 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1940106 | 0.82 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1939991 | 0.82 | PTGDR2 (1.00) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431703-B2 | Pyrrolopyridine compounds and their use in treating disease | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20080287416-A1 | Organic Compounds | NOVARTIS AG | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287416-A1 | Organic Compounds | OR10J3, OPRM1, OR51E2 | PTGDR2 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.